98%
921
2 minutes
20
Primary diffuse large B-cell lymphoma (DLBCL) of the colon, particularly involving the caecum, is rare and often poses a diagnostic challenge due to its non-specific presentation and the low incidence of colorectal involvement. Early recognition is crucial, as timely diagnosis and multidisciplinary management can significantly improve patient outcomes. A 29-year-old female presented with a two-week history of intermittent lower abdominal pain, progressive abdominal bloating, weight loss, night sweats, and bilateral ankle swelling over the last four weeks. Initial ultrasonography revealed a large soft tissue mass within the abdomen, initially reported as an ovarian mass; however, further evaluation, including CT imaging and colonoscopy, revealed an ulcerated, partially obstructing caecal mass. Histopathological examination of endoscopic biopsies confirmed DLBCL, non-germinal-centre B-cell subtype. PET imaging revealed multiple large, intensely fluorodeoxyglucose (FDG)-avid lymph nodes below the diaphragm forming a bulky nodal mass, along with a similarly FDG-avid caecal mass, strongly suggesting extra-nodal lymphoma involvement. The patient was subsequently managed with R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone) chemotherapy under the guidance of a multidisciplinary team. Primary colonic DLBCL is rare, accounting for a small fraction of colorectal malignancies. Its non-specific symptoms, including abdominal pain, altered bowel habits, and constitutional complaints, can mimic more common gastrointestinal conditions. This case highlights the importance of maintaining a broad differential diagnosis, especially in younger patients. While imaging modalities, endoscopic assessment, and histopathology are critical for accurate diagnosis, prompt oncologic consultation and chemotherapy remain central to management. A multidisciplinary treatment approach is vital in improving patient prognosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266697 | PMC |
http://dx.doi.org/10.7759/cureus.86150 | DOI Listing |
Virchows Arch
September 2025
Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Minas Gerais, Av. Antônio Carlos, Pampulha, Belo Horizonte, 31270-901, Brazil.
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs).
View Article and Find Full Text PDFPharm Res
September 2025
Mechanical and Aerospace Engineering Department, University of Texas at Arlington, 500 W First St, Rm 211, Arlington, TX, 76019, USA.
Objective: A fundamental understanding of drug diffusion and binding processes is critical for the design and optimization of a wide variety of drug delivery devices. Most of the past literature assume binding to occur uniformly throughout the tissue, or, at best, in specific layers of a multilayer tissue. However, in many realistic scenarios, such as in cancer-targeting drugs, drug binding occurs in discrete irregularly shaped regions.
View Article and Find Full Text PDFTransplant Cell Ther
September 2025
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Background: ZUMA-7 is the largest randomized controlled trial (RCT) for chimeric antigen receptor (CAR) T-cell therapy, which compared axicabtagene ciloleucel (axi-cel) to historical standard of care (HSoC) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Both arms of ZUMA-7 contained potentially curative treatments; however, differences in the treatment completion rate and timing to receive definitive treatment led to differences in the extent and timing of cure. Mixture cure modeling (MCM) has been suggested as a superior method in designing and powering clinical studies of curative therapies but also for extrapolation of long-term outcomes in simulation studies.
View Article and Find Full Text PDFJ Am Coll Health
September 2025
Hubbard School of Journalism and Mass Communication, University of Minnesota, Minneapolis, Minnesota, USA.
: An evolving THC product marketplace is diffusing through college campuses. It is essential to understand college students' THC knowledge, attitudes, practices and product packaging perceptions to identify campus health education and messaging strategies. : Participants were 30 undergraduate college students at a large-midwestern, public university.
View Article and Find Full Text PDFPhys Rev Lett
August 2025
Università degli Studi di Padova, Dipartimento di Fisica e Astronomia, Via Marzolo 8, 35131 Padova, Italy.
Feebly interacting particles, such as sterile neutrinos, dark photons, and axions, can be abundantly produced in the proto-neutron star (PNS) formed in core-collapse supernovae (CCSNe). These particles can decay into photons or charged leptons, depositing energy outside the PNS. Strong bounds on new particles can thus be derived from the observed luminosity of CCSNe, with even tighter bounds obtained from low-energy SNe observations.
View Article and Find Full Text PDF